At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 128 enrolled
Drug / intervention
Candesartan Cilexetil +2 moredrug
Likely dose
Candesartan Cilexetil 32mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy
In Brief
A Phase 4 clinical trial evaluating Candesartan Cilexetil and Candesartan Cilexetil 32mg for Non-diabetic Nephropathy With Hypertension. Completed, enrolled 128 participants across 1 site.
Detailed Summary
To determine the effective dose of candesartan cilexetil for reduction of urinary protein excretion in hypertensive patients with non-diabetic chronic kidney disease with baseline urinary protein/creatinine ratio between 500mg/g and 5000mg/g, by assessing the change in urinary protein/creatinine ratio from baseline to the end of 28-week treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedDec 2007
Primary CompletionAug 2009
TodayJul 2026
First PostedDec 14, 2007
Enrollment StartDec 1, 2007
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.6 years ago
Interventions
Candesartan Cilexetildrug
8 mg oral once daily dose
Candesartan Cilexetildrug
16 mg oral once daily dose
Candesartan Cilexetil 32mgdrug
32 mg oral once daily dose